Skip to main content

Medicine Matters oncology

Microneedle array-doxorubicin (MNA-D) is a novel delivery platform currently being studied in a phase I clinical trial for the treatment of patch/plaque disease in CTCL. Doxorubicin (Doxil®), a well-established, chemotherapeutic agent, is injected intralesionally, utilizing a dissolvable MNA. It is hypothesized that this mechanism will allow for direct delivery of chemotherapy to select cutaneous lesions while limiting systemic toxicity [7].